Guinea-Bissau Approves Controversial Hepatitis B Vaccine Trial Involving 14,000 Newborns

Authorities in Guinea-Bissau have reportedly approved a controversial hepatitis B vaccine trial involving 14,000 newborns, reigniting concerns over research ethics, infant protection and the future of vaccination programmes in countries with high rates of infection.

According to a report by The Guardian, Danish researchers intend to withhold the hepatitis B vaccine from half of the participating newborns during their first six weeks of life to assess the effects of different vaccination schedules.

The approximately $1.6 million study is funded by the United States Department of Health, according to the report. Its reported approval by an ethics committee in Denmark and officials in Guinea-Bissau follows a pause in January 2026 after the proposal sparked criticism from scientists and public health experts.

The trial has become controversial because hepatitis B vaccination at birth is an established public health measure designed to protect infants from infection, including transmission from infected mothers.

Why the Trial Has Sparked Controversy

Critics argue that deliberately delaying vaccination for some newborns could expose them to a preventable infection, particularly in a country where hepatitis B remains a significant public health concern.

The proposed study would compare outcomes between infants vaccinated at birth and those whose first dose is delayed for six weeks. Researchers aim to investigate the effects of the different approaches, but opponents have questioned whether the potential scientific benefits justify the risks to participating children.

The central ethical question is whether the research can be conducted without exposing infants to avoidable harm when an effective vaccine is already available.

Hepatitis B can cause both acute and chronic liver disease. Infection acquired during infancy is particularly concerning because babies and young children face a substantially greater risk of developing chronic infection than adults who acquire the virus.

Chronic hepatitis B can lead to serious complications later in life, including cirrhosis and liver cancer.

The World Health Organization recommends that all infants receive a hepatitis B vaccine dose as soon as possible after birth, preferably within 24 hours, followed by additional doses according to the recommended vaccination schedule.

Critics of the Guinea-Bissau study argue that any research involving a delay in this protection must demonstrate a compelling scientific justification and meet stringent standards for informed parental consent, independent ethical review and participant safety.

Guinea-Bissau Faces a Significant Hepatitis B Burden

The trial has attracted particular attention because of the reported prevalence of hepatitis B in Guinea-Bissau.

According to figures cited in the supplied report, more than 12 per cent of adults are estimated to be living with chronic hepatitis B, while infection among children under five is approximately 2 per cent.

The reported childhood prevalence is substantially above the World Health Organization's global target of reducing hepatitis B surface antigen prevalence among children under five to below 0.1 per cent by 2030.

These figures underline the importance of prevention strategies that protect children early in life.

Hepatitis B can be transmitted from an infected mother to her child during childbirth, as well as through exposure to infected blood and certain bodily fluids. Administering the vaccine shortly after birth is an important intervention for reducing mother-to-child transmission.

Guinea-Bissau plans to introduce hepatitis B vaccination for all newborns from 2028, according to the supplied report. The proposed trial therefore comes as the country prepares to strengthen protection against the virus.

US Funding Raises Further Questions

The study's reported US government funding has added another dimension to the controversy.

US Health Secretary Robert F. Kennedy Jr. has repeatedly expressed scepticism about vaccines. In late 2025, advisers to the US Centers for Disease Control and Prevention revised longstanding recommendations for universal hepatitis B vaccination of American infants, moving away from the previous blanket recommendation for all newborns.

Those policy changes have prompted debate over vaccine policy and public health decision-making in the United States.

However, the funding of the Guinea-Bissau study and the wider debate over US vaccination recommendations are separate issues. Establishing the scientific and ethical merits of the trial requires scrutiny of its research design, evidence, oversight arrangements and safeguards for participating infants.

The study's approval does not, by itself, establish that the proposed design is scientifically justified or that the concerns raised by critics have been resolved.

Africa CDC Raises Concerns as Discussions Continue

The Africa Centres for Disease Control and Prevention has opposed the proposed trial, according to the supplied report.

The organisation reportedly said that discussions between the United States and Guinea-Bissau were ongoing, with further details expected to be released.

The position highlights the importance of regional public health institutions in assessing research that could affect vaccination programmes and disease prevention across Africa.

International medical research conducted in lower-income countries is subject to particular scrutiny when participants may face heightened health risks or have limited access to healthcare.

Ethical safeguards generally require that researchers minimise avoidable harm, provide clear information to participants or their guardians, obtain informed consent and establish appropriate independent monitoring.

For a study involving newborns, these requirements are especially significant because infants cannot consent for themselves and depend entirely on adults and institutional safeguards to protect their interests.

The Importance of Protecting Newborns

The controversy raises broader questions about how medical research can generate useful scientific evidence while protecting vulnerable participants.

Researchers may investigate different vaccination schedules to understand safety, effectiveness and implementation challenges. However, when a proven preventive intervention exists, withholding or delaying it requires a strong scientific and ethical justification.

Independent reviewers must consider whether the research question can be answered through a less risky design, whether the expected benefits justify the potential risks and what measures will be in place if an infant becomes infected or experiences another adverse outcome.

Transparency about the study's protocol, consent process, funding arrangements and safety-monitoring procedures will be essential to public confidence.

It will also be important to clarify the precise objectives of the trial and how its findings are expected to inform hepatitis B vaccination policies.

Conclusion: A Critical Test for Research Ethics

The reported approval of the Guinea-Bissau hepatitis B vaccine trial has reopened a debate about the balance between scientific research and the protection of newborns.

With hepatitis B posing a substantial health burden in the country, the proposed six-week delay in vaccination for some infants has drawn criticism from scientists and public health advocates concerned about preventable infection.

The next steps will depend on the details of the approved protocol, the safeguards established by the researchers and the positions taken by national and regional public health authorities.